Suven Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on January 29, 2026. Allotment of 44,77,612 Equity Shares of the Company on preferential basis upon conversion 44,77,612 fully paid warrants
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts less than Nifty Microcap 250 and 0.7 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suven Life Sciences has informed the stock exchange about the outcome of its board meeting held on January 29, 2026. The board approved the allotment of 44,77,612 equity shares on a preferential basis. These shares were issued upon the conversion of an equal number of 44,77,612 fully paid warrants that were previously held by specific investors. Since these are warrant conversions, the warrant holders had already paid the exercise price earlier, so no fresh cash is being raised now. The allotment will increase the total outstanding share count of the company.
This is a technical allotment following earlier warrant conversions, so it dilutes existing shareholders' ownership proportionally by about 44.77 lakh new shares. Investors should check the company's shareholding pattern post-allotment to see if promoter or specific investor holdings have changed meaningfully.